UBS lowered the firm’s price target on Treace Medical (TMCI) to $8.60 from $10 and keeps a Neutral rating on the shares.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- Cautious Hold Rating for Treace Medical Concepts Amid Mixed Outlook and Revenue Uncertainty
- Treace Medical Concepts Reports Q1 2025 Financial Results
- Treace Medical reports Q1 EPS (25c), consensus (30c)
- Treace Medical sees Q2 revenue $224M-$230M, consensus $227.53M
- Class Action Filed Against Treace Medical Concepts, Inc. (TMCI) – June 10, 2025 Deadline to Join – Contact Levi & Korsinsky LLP